Citadel Advisors’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Citadel Advisors’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,400	Closed	-$30K	–	15293
2021 Q4	$30K	Sell	22,400 -11,500	-34%	-$27.2K	﹤0.01%	13483
2021 Q3	$99K	Buy	33,900 +6,200	+22%	+$20.6K	﹤0.01%	12896
2021 Q2	$97K	Sell	27,700 -78,400	-74%	-$269K	﹤0.01%	12950
2021 Q1	$363K	Buy	106,100 +55,700	+111%	+$1.05M	﹤0.01%	10408
2020 Q4	$968K	Sell	50,400 -14,500	-22%	-$224K	﹤0.01%	6866
2020 Q3	$872K	Buy	+64,900	New	+$1.84M	﹤0.01%	6275

Other funds holding ODT

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors's ODT Position: Q1 2022 in Review

Citadel Advisors sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 10,397 shares — an estimated $14K sold.

Citadel Advisors first reported a position in ODT in Q4 2018 and held it in 11 quarters. The position peaked at $1.94M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

Citadel Advisors reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Citadel Advisors sold 10,397 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $14K.
Citadel Advisors first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2018 and held it in 11 quarters.
Citadel Advisors's Odonate Therapeutics, Inc. Common Stock position peaked at $1.94M in Q2 2020.
8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.